ABSTRACT
Rationale Aerosol dispersion under various oxygen delivery modalities, including high flow nasal cannula, is a critical concern for healthcare workers who treat acute hypoxemic respiratory failure during the coronavirus disease 2019 pandemic. Effects of surgical masks on droplet and aerosol dispersion under oxygen delivery modalities are not yet clarified.
Objectives To visualize and quantify dispersion particles under various oxygen delivery modalities and examine the protective effect of surgical masks on particle dispersion.
Methods Three and five healthy men were enrolled for video recording and quantification of particles, respectively. Various oxygen delivery modalities including high flow nasal cannula were used in this study. Particle dispersions during rest breathing, speaking, and coughing were recorded and automatically counted in each condition and were evaluated with or without surgical masks.
Measurements and Main Results Coughing led to the maximum amount and distance of particle dispersion, regardless of modalities. Droplet dispersion was not visually increased by oxygen delivery modalities compared to breathing at room air. With surgical masks over the nasal cannula or high-flow nasal cannula, droplet dispersion was barely visible. Oxygen modalities did not increase the particle dispersion counts regardless of breathing pattens. Wearing surgical masks significantly decreased particle dispersion in all modalities while speaking and coughing, regardless of particle sizes, and reduction rates were approximately 95 and 80-90 % for larger (> 5 μm) and smaller (> 0.5 μm) particles, respectively.
Conclusions Surgical mask over high flow nasal canula may be safely used for acute hypoxemic respiratory failure including coronavirus disease 2019 patients.
Subject Category List 4.13 Ventilation: Non-Invasive/Long-Term/Weaning
*This article has an online data supplement, which is accessible from this issue’s table of content online at www.atsjournals.org.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support to conduct the study was provided by Fisher & Paykel Healthcare Co, Ltd. The funding source was not involved in the study design; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was approved by the Nagasaki University Graduate School of Biomedical Sciences Research Ethics Committee (Approval number: 20092503).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are not publicly available as containing information could compromise the privacy of research participants
